Journal
HEART FAILURE REVIEWS
Volume 21, Issue 4, Pages 455-462Publisher
SPRINGER
DOI: 10.1007/s10741-016-9525-z
Keywords
Arrhythmias; Heart failure with preserved ejection fraction; Sudden cardiac death
Categories
Funding
- National Institutes of Health
- Actelion
- Novartis
- European Union
- Health Resource Services Administration
- Food and Drug Administration
Ask authors/readers for more resources
The incidence and mechanisms of sudden cardiac death (SCD) among patients with heart failure with reduced ejection fraction have been well characterized. Conversely, limited data are available exploring the landscape of SCD in patients with heart failure with preserved ejection fraction (HFpEF). HFpEF is a heterogeneous clinical syndrome of increasing prevalence and is associated with substantial morbidity and mortality. This review will aim to contextualize recent data regarding rates and predictors of SCD in this growing population and to discuss the potential role of pharmacologic and device therapy for prevention of SCD within the at-risk HFpEF subset.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available